EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study



Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study



Journal of Urology 177(5): 1777-1781



Purpose: Patients with adverse pathological features are at high risk for recurrence following radical prostatectomy. To improve outcomes S in this population we performed a phase II study of adjuvant docetaxel in these high risk patients.Materials and Methods: Patients with nonmetastatic radical prostatectomy at greater than 50% risk for recurrence by 3 years were eligible. Pathological findings were centrally reviewed and risk assessment was based on a validated multivariate Cox proportional hazards model. Treatment consisted of 6 cycles of 35 mg/m(2) docetaxel weekly given 4 to 12 weeks following surgery. Progression was defined as a prostate specific antigen of 0.4 ng/ml or greater, radiological/pathological evidence of recurrent disease or death from any cause. To screen for the potential benefit of adjuvant weekly docetaxel we used nomogram predicted progression-free survival as a historical control.Results: A total of 77 patients were registered between April 2002 and January 2004. Two patients had grade IV hyperglycemia and 20 had grade III toxicity. At a median followup of 29.2 months (range 1.6 to 39.2) 46 of 76 evaluable cases (60.5%) progressed. Observed median progression-free survival was 15.7 months (95% CI 12.8-25.1). Predicted median progression-free survival in a matched population was 10 months. Seven patients died, including 4 of prostate cancer, I with intra-abdominal bleeding during treatment and 2 of pneumonia and sudden cardiac death, respectively, following treatment.Conclusions: Adjuvant docetaxel for prostate cancer is feasible with significant reversible but acceptable toxicity. The actual median progression-free survival of 15.7 months was longer than the nomogram predicted rate for this patient population. Adjuvant docetaxel treatment should be further evaluated in phase Ill trials in patients with high risk prostate cancer.

(PDF emailed within 0-6 h: $19.90)

Accession: 013630687

Download citation: RISBibTeXText

PMID: 17437819

DOI: 10.1016/j.juro.2007.01.028



Related references

Re: Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. European Urology 52(5): 1530-1531, 2007

A multi-institutional pilot study of adjuvant docetaxel for patients with prostate cancer at high risk for relapse after radical prostatectomy. Reviews in Urology 5 Suppl 3: S59-S64, 2006

A pilot multicenter phase II study of adjuvant docetaxel (D) for high risk prostate cancer (PC) patients (pts) after radical prostatectomy (RP): Preliminary data. Journal of Clinical Oncology 23(16_suppl): 4565-4565, 2016

Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy TAX-3501. Cancer, 2013

Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients. European Urology 68(3): 497-505, 2016

Phase II trial of weekly docetaxel (D) and complete androgen blockade (CAB) prior to radical prostatectomy (RP) in high-risk localized prostate cancer (PC) patients (pts). Journal of Clinical Oncology 24(18_suppl): 14515-14515, 2016

Veterans Affairs Cooperative Studies Program study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer. Urology 72(3): 474-480, 2008

Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials. Cancer 119(20): 3610-3618, 2013

Re: Predicting Prostate Cancer-specific Outcome After Radical Prostatectomy Among Men with Very High-risk cT3b/4 PCa: A Multi-institutional Outcome Study of 266 Patients. European Urology 70(3): 541-542, 2016

A multi-institutional analysis comparing adjuvant and salvage radiation therapy for high-risk prostate cancer patients with undetectable PSA after prostatectomy. RadioTherapy and Oncology 97(3): 474-479, 2011

Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer. Clinical Cancer Research 10(4): 1306-1311, 2004

Pilot trial of adjuvant paclitaxel (T) and estramustine phosphate (EMP) for high-risk prostate cancer patients after radical prostatectomy (RP). Journal of Clinical Oncology 23(16_suppl): 4775-4775, 2016

Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. European Urology 63(4): 693-701, 2013

Re: impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. Journal of Urology 189(3): 901-901, 2013

Weekly docetaxel and mitoxantrone prior to prostatectomy in patients with high risk localized prostate cancer. Journal of Urology 169(4 Supplement): 444, April, 2003